[Global Times Special Correspondent Liu Haoran] Following the remarkable progress made by the US pharmaceutical company's new crown vaccine, the main "cost-effective" vaccine of Oxford University and AstraZeneca will also be put into production soon.

However, according to a number of media reports, AstraZeneca vaccine appeared "oolong" in previous clinical tests, and the vaccine test data and effectiveness have caused many questions.

  According to a Reuters report on the 27th, earlier this week, AstraZeneca claimed that the company’s vaccine was "up to 90% effective" and did not show any serious side effects; however, the facts soon proved that this statement is quite " Moisture".

It turned out that the average efficacy of this vaccine was only maintained at about 70%, but 90% of the conclusions came from an "Oolong".

The British "Guardian" reported on the 26th that when injecting a group of 2,700 volunteers, researchers made a mistake. The first round of injections only used half the dose, and the second round only used the full dose; and the research team found out afterwards. This "half-dose + one-dose" injection method actually produced up to 90% effectiveness, much higher than the effectiveness of the complete two-dose vaccine (62%) given by 8895 volunteers.

Even Pangalos, director of AstraZeneca's drug development department, exclaimed that this was "hit the big luck", and the company has so far failed to provide a clear scientific explanation.

The company said on the 26th that it will launch a new round of global clinical trials on the "low-dose injection method" to verify the effectiveness of the "half dose + one dose" program.

  After the mistakes in the AstraZeneca vaccine trial were disclosed, the scientific community has widely questioned AstraZeneca's research results.

According to Reuters, many scientists believe that the sample size of the "half-dose + one-dose" program group is relatively too small, which makes it difficult to explain whether the 90% effectiveness number is a real result or an accidental result.

In addition, some experts pointed out that in the AstraZeneca vaccine trial, 90% of the effective subjects lacked elderly people over 55 years old, which may also affect the test results, because young people tend to have stronger immune responses.

  As to why the "half dose + one dose" program is more effective, the researchers are also "in the cloud."

Andrew Pollard, a professor at the University of Oxford and chief researcher of vaccine trials, speculated that this may be a'delicate balance' of the dose, and the appropriate dose of injection "just activates the immune system."

  Reuters quoted analysts as saying that data problems may hinder the approval of AstraZeneca vaccines in the United States and the European Union. British Health Secretary Hancock said at a press conference on the 26th that the government has formally requested the British Medicines and Medical Products Regulatory Agency to evaluate AstraZeneca’s vaccines. The European Medicines Agency said on the 26th that after receiving data on the effectiveness and safety of the AstraZeneca vaccine, it will conduct an evaluation in the next few weeks. CNN said on the 26th that it is not yet clear whether the US Food and Drug Administration (FDA) will give emergency authorization to AstraZeneca vaccine. An FDA spokesperson previously stated that the AstraZeneca vaccine test data is too small to determine the "importance" of the vaccine's results. The spokesperson revealed that AstraZeneca is negotiating with the FDA on this matter.